NASDAQ:AURA Aura Biosciences Q3 2024 Earnings Report $6.71 -0.41 (-5.76%) Closing price 07/18/2025 04:00 PM EasternExtended Trading$6.86 +0.15 (+2.16%) As of 07/18/2025 06:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast Aura Biosciences EPS ResultsActual EPS-$0.42Consensus EPS -$0.44Beat/MissBeat by +$0.02One Year Ago EPSN/AAura Biosciences Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAura Biosciences Announcement DetailsQuarterQ3 2024Date11/12/2024TimeAfter Market ClosesConference Call DateTuesday, November 12, 2024Conference Call Time9:30AM ETUpcoming EarningsAura Biosciences' Q2 2025 earnings is scheduled for Thursday, August 14, 2025, with a conference call scheduled on Thursday, August 7, 2025 at 7:15 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Aura Biosciences Earnings HeadlinesClearside Biomedical shares dip after announcing exploration of strategic alternativesJuly 17 at 1:27 PM | msn.comJMP maintains $19 target on Aura Biosciences stock after FDA insightsMay 24, 2025 | uk.investing.comMissed the Run So Far? This Is Your Second ChanceAccording to history, the final stretch of the crypto cycle is here — and this short window is where fortunes are made. Inside The Crypto Code Workshop, two experts reveal how to get positioned early, lock in profits, and access their top altcoin picks before the crowd. All attendees receive $10 in free Bitcoin just for showing up.July 20 at 2:00 AM | Crypto Swap Profits (Ad)Aura Biosciences Raises $69.9 Million in Public OfferingMay 16, 2025 | tipranks.comAura Biosciences Names Anthony Gibney Chief Financial, Business OfficerMay 16, 2025 | marketwatch.comAura Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comSee More Aura Biosciences Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Aura Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aura Biosciences and other key companies, straight to your email. Email Address About Aura BiosciencesAura Biosciences (NASDAQ:AURA) is a clinical‐stage biopharmaceutical company focused on the development of targeted therapies for oncology. Founded in 2016 and headquartered in San Diego, California, the company has pioneered a proprietary platform of virus‐like particles that are conjugated with a near‐infrared photoactivatable dye. This approach is designed to selectively bind to cancer cells and, upon activation with light, induce localized cytotoxic effects while minimizing damage to surrounding healthy tissue. The company’s lead product candidate, AU-011, is being evaluated for the treatment of primary ocular melanoma and head and neck cancers. AU-011 utilizes Aura’s proprietary virus‐like particles to deliver its photoactivatable payload directly to tumor cells. Once bound, the agent is activated by near‐infrared laser light, generating reactive oxygen species that destroy cancer cells and stimulate an anti‐tumor immune response. Preclinical and early clinical studies have demonstrated proof of concept for targeted cell killing and immunogenic cell death with a favorable safety profile. Aura Biosciences also maintains a growing pipeline of follow‐on candidates, including AU-012 and other next‐generation constructs engineered for specific tumor antigens. The company’s research and development operations span its San Diego headquarters as well as strategic collaborations in the United States and Europe. In addition to its clinical programs, Aura invests in translational research aimed at expanding its platform to new indications and enhancing the technology’s tissue penetration and immune potentiation capabilities. Under the leadership of Chief Executive Officer Chang‐gon Kim, Ph.D., Aura Biosciences has advanced from a venture‐backed startup through a successful initial public offering on NASDAQ in 2020. The company continues to engage with regulatory authorities, academic institutions and industry partners to accelerate clinical development and broaden patient access to its novel light‐activated oncology therapeutics.Written by Jeffrey Neal JohnsonView Aura Biosciences ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Netflix Q2 2025 Earnings: What Investors Need to KnowHow Goldman Sachs Earnings Help You Strategize Your PortfolioCitigroup Earnings Could Signal What’s Next for Markets3 Analysts Set $600 Target Ahead of Microsoft EarningsTesla: 2 Plays Ahead of Next Week's Earnings ReportFastenal Surges After Earnings Beat, Tariff Risks Loom3 Catalysts Converge on Intel Ahead of a Critical Earnings Report Upcoming Earnings NXP Semiconductors (7/21/2025)Verizon Communications (7/21/2025)Comcast (7/22/2025)Intuitive Surgical (7/22/2025)Texas Instruments (7/22/2025)America Movil (7/22/2025)Chubb (7/22/2025)Canadian National Railway (7/22/2025)Capital One Financial (7/22/2025)Danaher (7/22/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
